Zensun (Shanghai) Sci & Tech Co., Ltd.

Zensun (Shanghai) Sci & Tech Co., Ltd. (泽生科技) is a Chinese biopharmaceutical company headquartered in Shanghai that focuses on the discovery and development of innovative, first-in-class biologic medicines for serious and life-threatening unmet medical needs. The company describes itself as "A Leading Chinese Biotech Company Developing Novel Medicines as First-in-Class for Global Market" and organizes its research around two basic areas: cell signaling and energy metabolism. Its scientific identity is built on cardiomyocyte therapy — a mechanism-based approach that targets the fundamental biology of disease rather than merely treating symptoms. The company's flagship asset is Neucardin® (recombinant human Neuregulin-1, rhNRG-1), a genetically engineered biologic developed as a first-in-class therapy for heart failure. Zensun is advancing Neucardin® across multiple cardiovascular indications, including heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and acute myocardial infarction (AMI). The U.S. Food and Drug Administration (FDA) granted Fast Track designation to the investigation of Neucardin for chronic heart failure, a regulatory milestone the company highlights prominently. Beyond Neucardin®, the pipeline includes additional novel candidates such as ZS-05, ZS-06, and ZS-07, as well as gene therapy constructs and new medical devices in development. Zensun's origins trace to a scientific discovery made in 1998 in Sydney, Australia, by Dr. Mingdong Zhou, then director of a cell signaling research center and an independent principal investigator. Dr. Zhou identified that Neuregulin-1 (NRG-1), a signal protein molecule derived from the human body, acts as an agonist to the ErbB3/4 receptor and plays a crucial role not only in heart development but also in repairing damaged cardiomyocyte structure, strengthening the attachment of the septum of cardiac muscle cells, and improving sarcomere arrangement. This insight became the foundation of the company's cardiomyocyte therapy platform. Zensun has since accumulated what it describes as twenty years of innovative research and development in science and drug discovery, positioning itself as a pioneer and leader in revolutionary cardiomyocyte therapies worldwide. The company operates with a global outlook, collaborating with international research institutions. Notably, Zensun has partnered with the Leibniz-Institut für Alternsforschung–Fritz-Lipmann-Institut e.V. to conduct a preclinical study of Neucardin® for the treatment of Schwannomas. Zensun has also attracted international investors and reports having successfully raised approximately ¥504 million (US$76 million) in financing. Its stated tenet, "Healing-for-Life" (泽润生民，德周化宇), reflects its ambition to transform the lives of heart failure patients by providing drugs that treat the disease rather than only its symptoms. The company maintains an active investor relations function and communicates progress through press releases and media announcements.

Zensun's scientific foundation was laid in 1998 in Sydney, Australia, when Dr. Mingdong Zhou, then director of a cell signaling research center and an independent principal investigator, made a discovery in a molecular biology experiment. He found that Neuregulin-1 (NRG-1), a signal protein molecule derived from the human body, acts as an agonist to the ErbB3/4 receptor. This signaling molecule not only plays a crucial role in heart development but also repairs damaged cardiomyocyte structure, strengthens the attachment of the septum of cardiac muscle cells, and improves the arrangement of sarcomere. Dr. Zhou proposed to the international community the concept of using NRG-1 as a therapy for heart failure, building on earlier work such as Liu, X., Zhou, M. et al. (1998) in PNAS, which showed that Neuregulin-1 knockout mice died at the embryonic period with abnormal heart development, and Professor Kenneth R. Chien's report that conditional knockout of ErbB2, the receptor of Neuregulin-1, led to dilated cardiomyopathy. These studies collectively demonstrated the vital role of Neuregulin-1 in heart development and in maintaining normal heart function. Building on this discovery, Zensun (Shanghai) Sci & Tech Co., Ltd. was established in Shanghai, China, as a biopharmaceutical company dedicated to developing innovative first-in-class bio-therapeutic products for serious and life-threatening unmet medical needs. The company adopted the tenet "Healing-for-Life" (泽润生民，德周化宇) and focused its research on two basic areas: cell signaling and energy metabolism. Its core technology, cardiomyocyte therapy, is based on targeting the fundamental principles of disease and developing drugs through mechanism-of-action-based research. Over what the company describes as twenty years of innovative research and development in science and drug discovery, Zensun has built a pipeline of novel therapeutics with new drug targets, new mechanisms, and new indications. The flagship product is Neucardin® (recombinant human Neuregulin-1, rhNRG-1), a genetically engineered biologic developed as a first-in-class treatment for heart failure. Zensun has advanced Neucardin® into development for multiple cardiovascular indications, including heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and acute myocardial infarction (AMI). The investigation of Neucardin for chronic heart failure received Fast Track designation from the U.S. Food and Drug Administration, a significant regulatory recognition. The pipeline also includes ZS-05, ZS-06, and ZS-07, as well as a gene therapy construct (rAAV9.cMLCK) and new medical devices in development. Zensun has pursued a global strategy, gathering experts and pioneers in medical research from throughout the world and attracting international investors. The company successfully raised approximately ¥504 million (US$76 million). It has also entered into research collaborations, such as the partnership with the Leibniz-Institut für Alternsforschung–Fritz-Lipmann-Institut e.V. to conduct a preclinical study of Neucardin® for the treatment of Schwannomas. Headquartered in Shanghai, Zensun continues to position itself as a pioneer and leader in revolutionary cardiomyocyte therapies worldwide, aiming to transform the lives of heart failure patients by providing drugs that treat the disease rather than the symptoms.

• 1998

  Dr. Mingdong Zhou discovers that Neuregulin-1 (NRG-1) acts as an agonist to the ErbB3/4 receptor, repairs damaged cardiomyocyte structure, and improves sarcomere arrangement, proposing NRG-1 as a heart failure therapy.

• Zensun (Shanghai) Sci & Tech Co., Ltd. is founded in Shanghai, China, focusing on first-in-class bio-therapeutics.

• Zensun successfully raises approximately ¥504 million (US$76 million).

• The investigation of Neucardin for chronic heart failure receives Fast Track designation from the U.S. FDA.

• Zensun collaborates with the Leibniz-Institut für Alternsforschung–Fritz-Lipmann-Institut e.V. to conduct a preclinical study of Neucardin® for the treatment of Schwannomas.

First-in-class biologic therapies for cardiovascular disease, with a focus on cardiomyocyte therapy and global markets.

• Neucardin® (recombinant human Neuregulin-1, rhNRG-1)

  A novel genetically engineered biologic developed as a first-in-class therapy for heart failure, targeting HFrEF, HFpEF, and AMI.

• ZS-05

  A pipeline candidate in development.

• ZS-06

  A pipeline candidate in development.

• ZS-07

  A pipeline candidate in development.

• rAAV9.cMLCK gene therapy construct

  A gene therapy construct in development.

• Unconfirmed

  Shanghai ZeSheng Technology IPO review terminated[5]泽生科技科创板IPO审核终止guba.eastmoney.com

  The Shanghai Stock Exchange terminated its review of Shanghai ZeSheng Technology's application for an initial public offering and listing on the STAR Market after the issuer withdrew its application or its sponsor withdrew sponsorship.

1. 1泽生科技官方网站zensunus.com
2. 2泽生科技 - 关于我们zensunus.com
3. 3泽生科技 - 历史zensunus.com
4. 4Wikidata: Zensun (China)wikidata.org
5. 5泽生科技科创板IPO审核终止guba.eastmoney.com